A systematic review and meta-analysis of randomized controlled trials on SGLT2i in T2DM patients highlighted that no significant difference was noted in the occurrence of AF in SGLT2-i patients (26). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.